Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,034 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03059485 | DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission | active not recruiting | Phase 2 | 82 | Beth Israel Deaconess Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03597321 | Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML(ELIT-AML01) | active not recruiting | Phase 2 | 124 | Institut Paoli-CalmettesOTHER | 1 | Sep 29, 2026 |
| clinicaltrials |
| NCT03679650 | Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients | active not recruiting | Phase 1 | 28 | Beth Israel Deaconess Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05768711 | Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)(AVENHIR) | active not recruiting | Phase 2 | 44 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03560752 | CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant | active not recruiting | Phase 1 | 34 | City of Hope Medical CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05015426 | Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT | active not recruiting | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05025488 | Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm | active not recruiting | Phase 1 | 7 | Marina KremyanskayaOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06651229 | A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms | active not recruiting | Phase 1 | 85 | Janssen Research & Development, LLCINDUSTRY | 3 | Sep 28, 2026 | clinicaltrials |
| NCT03779854 | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05453903 | A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | active not recruiting | Phase 1 | 196 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT05548062 | Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera(Prospero) | active not recruiting | — | 242 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06618001 | A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms | active not recruiting | Phase 1 | 64 | Janssen Research & Development, LLCINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT04219163 | Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen | active not recruiting | Phase 1 | 18 | Baylor College of MedicineOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT02392429 | FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia | active not recruiting | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03839771 | A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy(HOVON150AML) | active not recruiting | Phase 3 | 968 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 15 | Sep 22, 2026 | clinicaltrials |
| NCT05035706 | Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors | active not recruiting | Early Phase 1 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05201066 | Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. | active not recruiting | Phase 2 | 33 | Novartis PharmaceuticalsINDUSTRY | 15 | Sep 22, 2026 | clinicaltrials |
| NCT02782546 | Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation | active not recruiting | Phase 2 | 60 | Washington University School of MedicineOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06379360 | Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients | active not recruiting | Phase 2 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT02530034 | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | active not recruiting | Phase 1 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04734990 | Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05007873 | ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase | active not recruiting | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06668558 | Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia(VERDI) | active not recruiting | Phase 2 | 28 | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y MielodisplasiasOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07825207 | Observational Study on Eltrombopag in Hypocellular Myelodysplastic Neoplasms | active not recruiting | — | 100 | Fondazione Italiana Sindromi Mielodisplastiche-ETSOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT03816319 | TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts | active not recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 2 | Sep 16, 2026 | clinicaltrials |
| NCT04657081 | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | active not recruiting | Phase 1 / Phase 2 | 101 | Taiho Oncology, Inc.INDUSTRY | 3 | Sep 16, 2026 | clinicaltrials |
| NCT06226571 | A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | active not recruiting | Phase 1 | 96 | Syndax PharmaceuticalsINDUSTRY | 6 | Sep 16, 2026 | clinicaltrials |
| NCT07822789 | Chidamide in HR-AML | active not recruiting | — | 33 | Guangdong Second Provincial General HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03516279 | Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease | active not recruiting | Phase 2 | 40 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03849651 | TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies | active not recruiting | Phase 2 | 69 | St. Jude Children's Research HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02530463 | Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome | active not recruiting | Phase 2 | 99 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02689440 | Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia | active not recruiting | Phase 2 | 155 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04128501 | Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | active not recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06765876 | CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial(UHKT-CAR123-01) | active not recruiting | Early Phase 1 | 18 | Institute of Hematology and Blood Transfusion, Czech RepublicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01861314 | Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05520567 | A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 70 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT03953898 | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | active not recruiting | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05589896 | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | active not recruiting | Phase 1 / Phase 2 | 12 | Ossium Health, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07814170 | A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece | active not recruiting | N/A | 80 | University of West AtticaOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT01522976 | Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 2 | 282 | National Cancer Institute (NCI)NIH | 2 | Sep 9, 2026 | clinicaltrials |
| NCT02890329 | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | active not recruiting | Phase 1 | 54 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04227847 | A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | active not recruiting | Phase 1 | 170 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT06429098 | Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML | active not recruiting | Phase 2 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03386513 | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | active not recruiting | Phase 1 / Phase 2 | 179 | AbbVieINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT04655755 | Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04746235 | Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 2 | 85 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03722420 | Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) | active not recruiting | Phase 3 | 238 | Il-Yang Pharm. Co., Ltd.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04635384 | Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test(ACROBAT) | active not recruiting | — | 307 | CareDxINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT00843882 | Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia | active not recruiting | Phase 3 | 247 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04953780 | Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Diagnosed AML | active not recruiting | Phase 1 | 6 | West Virginia UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
Data updated 14 hours agoSource updated Sep 29, 2026source: clinicaltrials